1. Ode H, Saito A, Washizaki A, Seki Y, Yoshida T, Harada S, Ishii H, Shioda T, Yasutomi Y, Matano T, Miura T, Akari H*, Iwatani Y*. Development of a novel macaque-tropic HIV-1 adapted to cynomolgus macaques. Journal of General Virology 103, 001790, 2022.doi: 10.1099/jgv.0.001790
2. Mori M, Ode H, Kubota M, Nakata Y, Kasahara T, Shigemi U, Okazaki R, Matsuda M, Matsuoka K, Sugimoto A, Hachiya A, Imahashi M, Yokomaku Y, Iwatani Y: Nanopore sequencing for characterization of HIV-1 recombinant forms. Microbiol Spectr 10, e0150722, 2022.doi:10.1128/spectrum.01507-22
3. Ishii H, Terahara K, Nomura T, Okazaki M, Yamamoto H, Shu T, Sakawaki H, Miura T, Watkins DI, Matano T. Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8+ T cells but not CD4+ T cells. Mol Ther. 30, 2048-2057, 2022.doi: 10.1016/j.ymthe.2022.02.023
4. Ishii H, Nakamura-Hoshi M, Shu T, Matano T. Sendai virus particles carrying target virus glycoproteins for antibody induction. Vaccine. 40:2420-2431, 2022.doi: 10.1016/j.vaccine.2022.03.008.
5. Morizako N, Butlertanaka EP, Tanaka YL, Shibata H, Okabayashi T, Mekata H, Saito A. Generation of a bovine cell line for gene engineering using an HIV-1-based lentiviral vector. Sci Rep 18;12(1):16952, 2022.doi: 10.1038/s41598-022-20970-6.
6. Takeuchi R, Ogihara K, Fujimoto J, Sato K, Mase N, Yoshimura K, Harada S, Narumi T. Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds. Bioorg Med Chem Lett 69, 128768, 2022. doi: 10.1016/j.bmcl.2022.128768.
7. Hau TTT, Nishizawa M, Harada S, Phan MH, Kanno Y, Nomura T, Matsuoka S, Kawana-Tachikawa A, Hall WW, Matano T, Nguyen LAT, Yamamoto H. Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection. AIDS 36, 1629-1641, 2022.doi: 10.1097/QAD.0000000000003323.